While no anti-IFN-γ therapies are currently FDA-approved for autoimmune diseases, early-phase clinical trials in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis are ongoing. Here, IFNG is linked to multiple sclerosis.